Ask AI
ProCE Banner Activity

Guideline-Concordant Care of High-Risk HR-Positive/HER2-Negative Early Breast Cancer 

Slideset

Download this slideset to review the use of CDK4/6 inhibitors in high-risk HR-positive/HER2-negative early breast cancer. Topics covered include eligibility criteria, key clinical trial data, treatment decision-making based on NCCN guidelines, managing adverse events, and promoting adherence and persistence to oral oncology treatments.

Released: April 27, 2026

Share

Provided by

Provided by National Comprehensive Cancer Network in collaboration with Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.

Lilly

Novartis Pharmaceuticals Corporation

Partners

Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Target Audience

This activity has been designed to meet the educational needs of oncologists, nurse practitioners, physician associates, oncology nurses, pharmacists, and other healthcare professionals involved in the care of patients with HR-positive/HER2-negative early breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Collaborate with multidisciplinary colleagues to identify each patient with HR-positive/HER2-negative EBC who is eligible for CDK4/6 inhibitor treatment

  • Recommend the optimal CDK4/6 inhibitor treatment for each patient with HR-positive/HER2-negative EBC in alignment with NCCN Guidelines, high-level evidence, and expert-recommended best practices

  • Support open and frequent patient-clinician communication to enable effective counseling on the benefits vs potential risks of adjuvant CDK4/6 inhibitor treatment, reporting of patient-felt toxicities, and screening for barriers to adherence/persistence

  • Implement proactive toxicity monitoring, dose modification, and supportive care to enable patient adherence and persistence to CDK4/6 inhibitor treatment for HR-positive/HER2-negative EBC